Mainz Biomed N.V (NASDAQ: MYNZ)’s stock price has dropped by -14.02 in relation to previous closing price of 0.26. Nevertheless, the company has seen a gain of 3.63% in its stock price over the last five trading days. globenewswire.com reported 2024-11-29 that BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V.
Is It Worth Investing in Mainz Biomed N.V (NASDAQ: MYNZ) Right Now?
MYNZ has 36-month beta value of 0.13. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MYNZ is 17.46M, and currently, short sellers hold a 20.42% ratio of that float. The average trading volume of MYNZ on November 29, 2024 was 3.42M shares.
MYNZ’s Market Performance
MYNZ stock saw a decrease of 3.63% in the past week, with a monthly decline of -13.69% and a quarterly a decrease of -37.77%. The volatility ratio for the week is 13.16%, and the volatility levels for the last 30 days are 14.81% for Mainz Biomed N.V (MYNZ). The simple moving average for the past 20 days is -4.41% for MYNZ’s stock, with a -60.25% simple moving average for the past 200 days.
Analysts’ Opinion of MYNZ
H.C. Wainwright gave a rating of “Buy” to MYNZ, setting the target price at $25 in the report published on June 21st of the previous year.
MYNZ Trading at -13.56% from the 50-Day Moving Average
After a stumble in the market that brought MYNZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.70% of loss for the given period.
Volatility was left at 14.81%, however, over the last 30 days, the volatility rate increased by 13.16%, as shares sank -10.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.92% lower at present.
During the last 5 trading sessions, MYNZ rose by +3.63%, which changed the moving average for the period of 200-days by -78.42% in comparison to the 20-day moving average, which settled at $0.2303. In addition, Mainz Biomed N.V saw -81.03% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MYNZ
Current profitability levels for the company are sitting at:
- -31.23 for the present operating margin
- 0.57 for the gross margin
The net margin for Mainz Biomed N.V stands at -30.58. The total capital return value is set at -3.27.
Based on Mainz Biomed N.V (MYNZ), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -2.73.
Currently, EBITDA for the company is -25.01 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 22.05. The receivables turnover for the company is 1.82for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
To put it simply, Mainz Biomed N.V (MYNZ) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
